RESUMO
Eighty-eight women presenting with locally advanced or metastatic breast cancer were treated with tamoxifen alone. Estrogen and progesterone receptors (ER and PR) were immunocytochemically analysed in mammary tumour cells obtained by fine needle sampling from 73 patients. Of the breast carcinomas, 34.2% were ER+/PR+ and 43.8% were ER-/PR-. The ER+ content increased with age in postmenopausal women. After tamoxifen treatment objective remission occurred in 39.7% of the women. The overall response rate was 53.3% in the ER+/PR- group and 73.1% in the ER+/PR+ group. However, the response elicited in a case of the ER-/PR- phenotype justified the randomized use of tamoxifen among patients in Iraq where the necessary requirements for hormone receptor assessment are almost unavailable.
Assuntos
Antineoplásicos Hormonais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Antagonistas de Estrogênios/uso terapêutico , Tamoxifeno/uso terapêutico , Adulto , Distribuição por Idade , Fatores Etários , Idoso , Antineoplásicos Hormonais/farmacologia , Biópsia por Agulha , Neoplasias da Mama/classificação , Neoplasias da Mama/diagnóstico , Antagonistas de Estrogênios/farmacologia , Feminino , Humanos , Imuno-Histoquímica , Iraque , Pessoa de Meia-Idade , Fenótipo , Estudos Prospectivos , Receptores de Estrogênio/análise , Receptores de Estrogênio/efeitos dos fármacos , Receptores de Progesterona/análise , Receptores de Progesterona/efeitos dos fármacos , Indução de Remissão , Índice de Gravidade de Doença , Tamoxifeno/farmacologia , Fatores de Tempo , Resultado do TratamentoRESUMO
Eighty-eight women presenting with locally advanced or metastatic breast cancer were treated with tamoxifen alone. Estrogen and progesterone receptors [ER and PR] were immunocytochemically analysed in mammary tumour cells obtained by fine needle sampling from 73 patients. Of the breast carcinomas, 34.2% were ER+/PR+ and 43.8% were ER-/PR-. The ER+ content increased with age in postmenopausal women. After tamoxifen treatment objective remission occurred in 39.7% of the women. The overall response rate was 53.3% in the ER+/PR- group and 73.1% in the ER+/PR+ group. However, the response elicited in a case of the ER-/PR- phenotype justified the randomized use of tamoxifen among patients in Iraq where the necessary requirements for hormone receptor assessment are almost unavailable
